BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Toth K, Dhar D, Wold WS. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin Biol Ther 2010;10:353-68. [PMID: 20132057 DOI: 10.1517/14712590903559822] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Keshavarz M, Mohammad Miri S, Behboudi E, Arjeini Y, Dianat-Moghadam H, Ghaemi A. Oncolytic virus delivery modulated immune responses toward cancer therapy: Challenges and perspectives. Int Immunopharmacol 2022;108:108882. [PMID: 35623296 DOI: 10.1016/j.intimp.2022.108882] [Reference Citation Analysis]
2 Firoz A, Ali HM, Rehman S, Rather IA. Gastric Cancer and Viruses: A Fine Line between Friend or Foe. Vaccines 2022;10:600. [DOI: 10.3390/vaccines10040600] [Reference Citation Analysis]
3 Pierce KM, Miklavcic WR, Cook KP, Hennen MS, Bayles KW, Hollingsworth MA, Brooks AE, Pullan JE, Dailey KM. The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors. Nanomaterials (Basel) 2021;11:3018. [PMID: 34835785 DOI: 10.3390/nano11113018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Toth K, Tollefson AE, Chinnadurai G, Bellone CJ, Grandgenett DP, Morrison LA, Tavis JE. Biographical Feature: William S. M. Wold, Ph.D., 1944-2021. J Virol 2021;95:e0118421. [PMID: 34549981 DOI: 10.1128/JVI.01184-21] [Reference Citation Analysis]
5 Georgi F, Greber UF. The Adenovirus Death Protein - a small membrane protein controls cell lysis and disease. FEBS Lett 2020;594:1861-78. [PMID: 32472693 DOI: 10.1002/1873-3468.13848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
6 Khalil IR, Khechara MP, Kurusamy S, Armesilla AL, Gupta A, Mendrek B, Khalaf T, Scandola M, Focarete ML, Kowalczuk M, Radecka I. Poly-Gamma-Glutamic Acid (γ-PGA)-Based Encapsulation of Adenovirus to Evade Neutralizing Antibodies. Molecules 2018;23:E2565. [PMID: 30297641 DOI: 10.3390/molecules23102565] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
7 Li Y, Hong J, Oh JE, Yoon AR, Yun CO. Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer. Int J Cancer 2018;142:392-413. [PMID: 28929492 DOI: 10.1002/ijc.31060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
8 Gardeck AM, Sheehan J, Low WC. Immune and viral therapies for malignant primary brain tumors. Expert Opinion on Biological Therapy 2017;17:457-74. [DOI: 10.1080/14712598.2017.1296132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
9 Fang L, Cheng Q, Liu W, Zhang J, Ge Y, Zhang Q, Li L, Liu J, Zheng J. Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell. Cancer Biol Ther 2016;17:664-73. [PMID: 27195521 DOI: 10.1080/15384047.2016.1190485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, Kankainen M, Ristimäki A, Koski A, Liikanen I, Oksanen M, Nettelbeck DM, Kairemo K, Partanen K, Joensuu T, Kanerva A, Hemminki A. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy. Oncotarget 2015;6:4467-81. [PMID: 25714011 DOI: 10.18632/oncotarget.2901] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
11 Cheng PH, Rao XM, Duan X, Li XF, Egger ME, McMasters KM, Zhou HS. Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter. J Mol Med (Berl) 2015;93:211-23. [PMID: 25376708 DOI: 10.1007/s00109-014-1214-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
12 Prasad V, Suomalainen M, Pennauer M, Yakimovich A, Andriasyan V, Hemmi S, Greber UF. Chemical induction of unfolded protein response enhances cancer cell killing through lytic virus infection. J Virol 2014;88:13086-98. [PMID: 25187554 DOI: 10.1128/JVI.02156-14] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
13 Yang Y, Xue S, Lu Z, Xiao F, Yin Y, Zhang Q, Wu C, Wang H, Wang L. Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer. Gene Ther 2014;21:723-31. [DOI: 10.1038/gt.2014.46] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
14 Xu W, Zhang Z, Yang Y, Hu Z, Wang CH, Morgan M, Wu Y, Hutten R, Xiao X, Stock S, Guise T, Prabhakar BS, Brendler C, Seth P. Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases. Mol Ther 2014;22:1504-17. [PMID: 24791939 DOI: 10.1038/mt.2014.80] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
15 Dhar D, Toth K, Wold WS. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters. Cancer Gene Ther 2014;21:171-8. [PMID: 24722357 DOI: 10.1038/cgt.2014.13] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
16 Hendrickx R, Stichling N, Koelen J, Kuryk L, Lipiec A, Greber UF. Innate immunity to adenovirus. Hum Gene Ther 2014;25:265-84. [PMID: 24512150 DOI: 10.1089/hum.2014.001] [Cited by in Crossref: 136] [Cited by in F6Publishing: 133] [Article Influence: 17.0] [Reference Citation Analysis]
17 Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 2014;12:23-34. [PMID: 24292552 DOI: 10.1038/nrmicro3140] [Cited by in Crossref: 169] [Cited by in F6Publishing: 165] [Article Influence: 18.8] [Reference Citation Analysis]
18 Nakashima H, Chiocca EA. Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus. J Virol 2014;88:345-53. [PMID: 24155386 DOI: 10.1128/JVI.02668-13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
19 Cheng PH, Lian S, Zhao R, Rao XM, McMasters KM, Zhou HS. Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells. Virol J 2013;10:293. [PMID: 24059864 DOI: 10.1186/1743-422X-10-293] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
20 Choi Y, Chang J. Viral vectors for vaccine applications. Clin Exp Vaccine Res 2013;2:97-105. [PMID: 23858400 DOI: 10.7774/cevr.2013.2.2.97] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 5.9] [Reference Citation Analysis]
21 Wold WS, Toth K. Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res 2012;115:69-92. [PMID: 23021242 DOI: 10.1016/B978-0-12-398342-8.00003-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
22 Choi IK, Yun CO. Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther 2013;20:70-6. [PMID: 23306610 DOI: 10.1038/cgt.2012.95] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
23 Grünwald GK, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Göke B, Holm PS, Spitzweg C. Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus. Gene Ther. 2013;20:625-633. [PMID: 23038026 DOI: 10.1038/gt.2012.79] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
24 Seo J, Yun CO, Kwon OJ, Choi EJ, Song JY, Choi I, Cho KH. A proteoliposome containing apolipoprotein A-I mutant (V156K) enhances rapid tumor regression activity of human origin oncolytic adenovirus in tumor-bearing zebrafish and mice. Mol Cells 2012;34:143-8. [PMID: 22851220 DOI: 10.1007/s10059-012-2291-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
25 Potts KG, Hitt MM, Moore RB. Oncolytic viruses in the treatment of bladder cancer. Adv Urol 2012;2012:404581. [PMID: 22899907 DOI: 10.1155/2012/404581] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
26 Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658-670. [PMID: 22781695 DOI: 10.1038/nbt.2287] [Cited by in Crossref: 804] [Cited by in F6Publishing: 840] [Article Influence: 80.4] [Reference Citation Analysis]
27 Zhang Z, Hu Z, Gupta J, Krimmel JD, Gerseny HM, Berg AF, Robbins JS, Du H, Prabhakar B, Seth P. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host. Cancer Gene Ther 2012;19:630-6. [PMID: 22744210 DOI: 10.1038/cgt.2012.41] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
28 Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen YJ, Zhang Z, Du H, Brendler CB, Xiao X. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther. 2012;23:871-882. [PMID: 22551458 DOI: 10.1089/hum.2012.040] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
29 Wollmann G, Ozduman K, van den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J 2012;18:69-81. [PMID: 22290260 DOI: 10.1097/PPO.0b013e31824671c9] [Cited by in Crossref: 112] [Cited by in F6Publishing: 112] [Article Influence: 11.2] [Reference Citation Analysis]
30 Aurisicchio L, Ciliberto G. Genetic cancer vaccines: current status and perspectives. Expert Opin Biol Ther 2012;12:1043-58. [PMID: 22577875 DOI: 10.1517/14712598.2012.689279] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
31 Hofacre A, Wodarz D, Komarova NL, Fan H. Early infection and spread of a conditionally replicating adenovirus under conditions of plaque formation. Virology 2012;423:89-96. [PMID: 22192628 DOI: 10.1016/j.virol.2011.11.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
32 Lee K, Yun ST, Yun CO, Ahn BY, Jo EC. S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma. Gene Ther 2012;19:967-77. [PMID: 22033466 DOI: 10.1038/gt.2011.168] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
33 Aurisicchio L, Ciliberto G. Emerging cancer vaccines: the promise of genetic vectors. Cancers (Basel) 2011;3:3687-713. [PMID: 24212974 DOI: 10.3390/cancers3033687] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
34 Wu Y, Zhang X, Wang X, Wang L, Hu S, Liu X, Meng S. Apoptin enhances the oncolytic properties of Newcastle disease virus. Intervirology 2012;55:276-86. [PMID: 21865658 DOI: 10.1159/000328325] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
35 Abel T, Kreppel F, Ogris M, Büning H. [When gene vectors are equipped with the correct key, the cell surface can be targeted]. Pharm Unserer Zeit 2011;40:225-38. [PMID: 21698612 DOI: 10.1002/pauz.201100418] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
36 Viru L, Heller G, Lehto T, Pärn K, El Andaloussi S, Langel Ü, Merits A. Novel viral vectors utilizing intron splice-switching to activate genome rescue, expression and replication in targeted cells. Virol J 2011;8:243. [PMID: 21595942 DOI: 10.1186/1743-422X-8-243] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
37 Chen W, Wu Y, Liu W, Wang G, Wang X, Yang Y, Chen W, Tai Y, Lu M, Qian Q, Zhang Q, Chen G. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. Cancer Lett 2011;307:93-103. [PMID: 21504839 DOI: 10.1016/j.canlet.2011.03.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
38 Leja J, Yu D, Nilsson B, Gedda L, Zieba A, Hakkarainen T, Åkerström G, Öberg K, Giandomenico V, Essand M. Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. Gene Ther 2011;18:1052-62. [PMID: 21490682 DOI: 10.1038/gt.2011.54] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
39 Bagheri N, Shiina M, Lauffenburger DA, Korn WM. A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition. PLoS Comput Biol 2011;7:e1001085. [PMID: 21379332 DOI: 10.1371/journal.pcbi.1001085] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
40 Uil TG, Vellinga J, de Vrij J, van den Hengel SK, Rabelink MJ, Cramer SJ, Eekels JJ, Ariyurek Y, van Galen M, Hoeben RC. Directed adenovirus evolution using engineered mutator viral polymerases. Nucleic Acids Res 2011;39:e30. [PMID: 21138963 DOI: 10.1093/nar/gkq1258] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
41 Kanegae Y, Terashima M, Kondo S, Fukuda H, Maekawa A, Pei Z, Saito I. High-level expression by tissue/cancer-specific promoter with strict specificity using a single-adenoviral vector. Nucleic Acids Res 2011;39:e7. [PMID: 21051352 DOI: 10.1093/nar/gkq966] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
42 Toth K, Wold WS. Increasing the efficacy of oncolytic adenovirus vectors. Viruses 2010;2:1844-66. [PMID: 21994711 DOI: 10.3390/v2091844] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]